Accuray Incorporated reported a net revenue of $97.5 million for the second quarter of fiscal year 2021, which includes $21.3 million of system revenue in China. The company's GAAP operating income was $8.2 million and GAAP net income was $4.8 million. Adjusted EBITDA grew to $13.5 million. They also received FDA clearance for ClearRT™ Helical kVCT Imaging for the Radixact® System.
Net revenue of $97.5 million including $21.3 million of system revenue in China.
Gross orders of $75.4 million, ending backlog of $596.2 million, an increase of 11 percent from December 31, 2019.
GAAP operating income of $8.2 million and GAAP net income of $4.8 million, compared to GAAP operating income of $3.6 million and GAAP net income of $10.7 million in the prior year second quarter.
Adjusted EBITDA grew to $13.5 million from $7.1 million in the prior year second quarter.
Accuray believes it is prudent to refrain from providing financial guidance for fiscal year 2021 due to the continued evolution of the COVID-19 pandemic and the uncertainty surrounding its impact on the global economy and the healthcare industry.
Visualization of income flow from segment revenue to net income